New Challenges in the Diagnosis of Kidney Damage Due to Immune Checkpoint Inhibitors Therapy: An Observational Clinical Study

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 Aug 12

PMID 37568887

Authors

Laura Vicente-Vicente

Alfredo G Casanova

Javier Tascon

Marta Prieto

Ana I Morales

Affiliations

Soon will be listed here.

Abstract

In recent years, immunotherapy has been postulated as one of the most effective strategies in the fight against cancer. The greatest success in this field has been achieved with the inhibition of molecules involved in slowing down the adaptive immune response by immune checkpoint inhibitors (ICIs). Despite its efficacy, ICI treatment has side effects. Regarding kidney damage, it is estimated that 4.9% of patients treated with ICIs develop renal injury. Furthermore, cancer patients who develop renal dysfunction have a worse prognosis. Current diagnostics are insufficient to predict the underlying renal injury and to identify the type of damage. Our hypothesis is that the renal injury could be subclinical, so the possibility of using new urinary biomarkers could be a useful diagnostic tool that would allow these patients to be managed in a preventive (risk biomarkers) and early (early biomarkers) way and even to clarify whether the renal damage is due to this therapy or to other factors (differential diagnostic biomarkers). A prospective study to validate risk and early and differential biomarkers in patients treated with ICIs is proposed to test this hypothesis. The results derived from this study will improve the clinical practice of cancer treatment with ICIs and therefore the life expectancy and quality of life of patients. Trial Registration: ClinicalTrials.gov, NCT04902846.

References

Belliere J, Mazieres J, Meyer N, Chebane L, Despas F . Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. Diagnostics (Basel). 2021; 11(7). PMC: 8303282. DOI: 10.3390/diagnostics11071187. View

Tinawi M, Bastani B . Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond. Cureus. 2021; 12(12):e12204. PMC: 7817088. DOI: 10.7759/cureus.12204. View

Waikar S, Bonventre J . Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol. 2009; 20(3):672-9. PMC: 2653692. DOI: 10.1681/ASN.2008070669. View

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Vicente-Vicente L, Ferreira L, Gonzalez-Buitrago J, Lopez-Hernandez F, Lopez-Novoa J, Morales A . Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats. Toxicology. 2012; 304:83-91. DOI: 10.1016/j.tox.2012.12.006. View

Franzin R, Netti G, Spadaccino F, Porta C, Gesualdo L, Stallone G . The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. Front Immunol. 2020; 11:574271. PMC: 7580288. DOI: 10.3389/fimmu.2020.574271. View

Wanchoo R, Karam S, Uppal N, Barta V, Deray G, Devoe C . Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol. 2017; 45(2):160-169. DOI: 10.1159/000455014. View

Sorah J, Rose T, Radhakrishna R, Derebail V, Milowsky M . Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity. J Immunother. 2020; 44(3):127-131. PMC: 7933112. DOI: 10.1097/CJI.0000000000000338. View

Vicente-Vicente L, Sanchez-Juanes F, Garcia-Sanchez O, Blanco-Gozalo V, Pescador M, Sevilla M . Sub-nephrotoxic cisplatin sensitizes rats to acute renal failure and increases urinary excretion of fumarylacetoacetase. Toxicol Lett. 2015; 234(2):99-109. DOI: 10.1016/j.toxlet.2014.11.033. View

10.

Hofmann L, Forschner A, Loquai C, Goldinger S, Zimmer L, Ugurel S . Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016; 60:190-209. DOI: 10.1016/j.ejca.2016.02.025. View

11.

Quiros Y, Ferreira L, Sancho-Martinez S, Gonzalez-Buitrago J, Lopez-Novoa J, Lopez-Hernandez F . Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein. Kidney Int. 2010; 78(10):1006-15. DOI: 10.1038/ki.2010.267. View

12.

Francisco L, Sage P, Sharpe A . The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236:219-42. PMC: 2919275. DOI: 10.1111/j.1600-065X.2010.00923.x. View

13.

Flynn M, Larkin J . Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. Expert Opin Pharmacother. 2017; 18(14):1477-1490. DOI: 10.1080/14656566.2017.1369956. View

14.

Seethapathy H, Herrmann S, Sise M . Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management. Kidney Med. 2021; 3(6):1074-1081. PMC: 8664750. DOI: 10.1016/j.xkme.2021.08.008. View

15.

Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass W, Tchakarov A . Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019; 7(1):2. PMC: 6322290. DOI: 10.1186/s40425-018-0478-8. View

16.

Abdel-Rahman O, Fouad M . A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy. 2016; 8(5):665-74. DOI: 10.2217/imt-2015-0020. View

17.

Perazella M, Sprangers B . Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. Clin Kidney J. 2021; 14(5):1301-1306. PMC: 8087122. DOI: 10.1093/ckj/sfab052. View

18.

Zhao D, Wang W, Tang T, Zhang Y, Yu C . Current progress in artificial intelligence-assisted medical image analysis for chronic kidney disease: A literature review. Comput Struct Biotechnol J. 2023; 21:3315-3326. PMC: 10275698. DOI: 10.1016/j.csbj.2023.05.029. View

19.

Sznol M, Ferrucci P, Hogg D, Atkins M, Wolter P, Guidoboni M . Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017; 35(34):3815-3822. DOI: 10.1200/JCO.2016.72.1167. View

20.

Paniagua-Sancho M, Quiros Y, Casanova A, Blanco-Gozalo V, Agueros-Blanco C, Benito-Hernandez A . Urinary Plasminogen Activator Inhibitor-1: A Biomarker of Acute Tubular Injury. Am J Nephrol. 2021; 52(9):714-724. DOI: 10.1159/000518455. View